Coronavirus disease 2019, superinfections, and antimicrobial development: what can we expect?

CJ Clancy, MH Nguyen - Clinical Infectious Diseases, 2020 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) arose at a time of great concern about
antimicrobial resistance (AMR). No studies have specifically assessed COVID-19 …

The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later

R Laxminarayan, T Van Boeckel, I Frost… - The Lancet Infectious …, 2020 - thelancet.com
Summary In 2013, a Lancet Infectious Diseases Commission described the state of
antimicrobial resistance worldwide. Since then, greater awareness of the public health …

Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study

IA Dutescu, SA Hillier - Infection and drug resistance, 2021 - Taylor & Francis
Antibiotic resistance is an urgent public health threat that has received substantial attention
from the world's leading health agencies and national governmental bodies alike. However …

Strategies to improve antibiotic access and a way forward for lower middle-income countries

H Wasan, KH Reeta, YK Gupta - Journal of Antimicrobial …, 2024 - academic.oup.com
Antibiotics have substantially improved life expectancy in past decades through direct
control or prevention of infections. However, emerging antibiotic resistance and lack of …

Emerging antibiotic resistance: Why we need new antibiotics!

AF Widmer - Swiss Medical Weekly, 2022 - smw.ch
Antibiotics have revolutionised medicine: Today, deadly infections such as meningitis and
pneumonia can be treated by appropriate antibiotics with a treatment success rate of up to …

Financing pull mechanisms for antibiotic-related innovation: opportunities for Europe

C Årdal, Y Lacotte, MC Ploy - Clinical Infectious Diseases, 2020 - academic.oup.com
Antibiotic innovation is in serious jeopardy as companies continue to abandon the market
due to a lack of profitability. Novel antibiotics must be used sparingly to hinder the spread of …

Antibiotic development incentives that reflect societal value of antibiotics

HW Boucher, TM File, VG Fowler… - Clinical Infectious …, 2021 - academic.oup.com
To the Editor—Rome and Kesselheim [1] claimed that rewarding developers of novel
antibiotics with transferable exclusivity vouchers is an expensive approach to promoting …

Transferable exclusivity vouchers and incentives for antimicrobial development in the European Union

VL Van de Wiele, A Raymakers… - Journal of Law …, 2023 - cambridge.org
The European Commission's proposal to address antimicrobial resistance using
transferable exclusivity vouchers (TEVs) is fundamentally flawed. European policymakers …

[HTML][HTML] Overview of the market for novel medicines in the WHO European Region

C Årdal, R Lopert, J Mestre-Ferrandiz - 2022 - europepmc.org
Abstract The Oslo Medicines Initiative (OMI) is a platform through which stakeholders can
collaborate to develop ways of achieving better, more affordable access to novel, high …

The Economics of transferable patent extensions

P Dubois, PH Moisson, J Tirole - 2022 - publications.ut-capitole.fr
Faced with a scarcity of treatments for neglected diseases, experts and governmental
organizations have lately proposed to build strong pull incentives around transferable …